Home » Newsletters » BioWorld Science

BioWorld Science

March 6, 2015

View Archived Issues

FDA grants rituximab orphan drug status for pemphigus vulgaris

Pluristem and Hadassah Medical Center report data from preclinical PLX-R18 study

New grant to support biomarker-led development of irofulven for mCRPC

Phase II results presented for a urothelial carcinoma combination therapy

Novel AR and CYP17A1 dual inhibitor shows significant antitumor activity

Vanda reports topline phase II results for tradipitant

EC-1169 drug conjugate is safe in mCRPC patients

[68Ga]PSMA PET/CT shows promise for detecting prostate cancer recurrence

Sirona Biochem reports preclinical toxicology results for SBM-TFC-039

Enrollment begins in phase I/IIa trial of AST-OPC1 in complete cervical spinal cord injury

Arrowhead Research acquires Novartis' RNAi R&D portfolio

Spectrum Pharmaceuticals in-licenses poziotinib from Hanmi Pharmaceuticals

Galapagos patents new ephrin inhibitors

Novartis discloses new MEK inhibitors

arGEN-X exercises option to license antibody candidate for cancer immunotherapy

Sanofi presents new anti-PAI-1 MAbs

Janssen describes Ca(v) 2.2 channel blockers

Bristol-Myers Squibb reports novel GR and AP-1 modulators

Blueprint Medicines and Alexion partner to develop kinase-targeting drugs for rare genetic disease

Grifols agrees to make major equity investment in Alkahest

Oraya IRay Radiotherapy system receives CE Mark extension for choroidal metastases

Medtronic invests in Flex Pharma IPO

Calithera gains worldwide license to TransTech's hexokinase-2 inhibitors

Quantum Genomics initiates phase IIa trial of QGC-001 for hypertension

Novel DNA-based therapy shows efficacy for advanced ovarian cancer treatment

AstraZeneca and University of Cambridge collaborate on start-up venture program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...